EvogeneとPure Capital Groupが協力協定を締結
EvogeneとPure Capital Groupは、違いを解決し、取締役会を再構成するための協力契約を締結しました。これにより、現在の2人の取締役がPure Capital Groupから推薦された候補者に置き換えられます。
なぜ重要か. この合意により、Evogeneは長期的な運用の安定性を得ることができ、AIを駆使した小分子の発見および最適化の目標に集中できるようになります。
01
誰に影響するか
- 1Evogene Ltd.
- で事業展開 →事実
- を使用 →事実
- で事業展開 →事実
- で事業展開 →事実
02
根拠
- PPR Newswire news releases企業開示2026-10-07 04:00
Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries
- PPR Newswire news releases企業開示2026-10-07 04:00
its goal of becoming a world leader in AI-driven small-molecule discovery and optimization for the pharmaceutical and ag-chemical industries
- PPR Newswire news releases企業開示2026-10-07 04:00
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters.
- PPR Newswire news releases企業開示2026-10-07 04:00
the reconstituted Board will comprise seven directors, including four nominated by the Pure Capital Group
- PPR Newswire news releases企業開示2026-10-07 04:00
Evogene Ltd. (Nasdaq: EVGN ) (TASE: EVGN)
- PPR Newswire news releases企業開示2026-10-07 04:00
Under the terms of the Agreement, two current directors, Dr. Yael Margolin and Mr. Yoshinori Oikawa, who resigned from the Board will be replaced by Pure Capital Group nominees Dr.
- PPR Newswire news releases企業開示2026-10-07 04:00
REHOVOT, Israel , Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN ) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a…